Taysha Gene Therapies Inc. (TSHA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
Taysha Gene Therapies: Shortened Timeline Increases The Potential
Taysha Gene Therapies is now a one-drug company, fully reliant on TSHA-102 for Rett syndrome after discontinuing its previous pipeline. I rate TSHA as a Buy, citing strong cash reserves, promising early TSHA-102 data, and an accelerated FDA pathway skipping Phase 3. TSHA-102's miRARE technology offers a safety edge over competitor NGN-401, with pivotal data expected in late 2026 and potential commercialization by 2027/2028.
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,898,112 shares of the company's stock, valued at approximately $6,207,000. Taysha Gene Therapies comprises 3.8% of Ally Bridge
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. ( TSHA ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran Alam - CFO & Corporate Secretary Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Gil Blum - Needham & Company, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Presentation Operator Good day, everyone and welcome to The Taysha Gene Therapies Third Quarter 2025 Earnings Call.
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.09 per share a year ago.
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Kamran Alam - CFO & Corporate Secretary Sean P. Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Conference Call Participants Biren N.
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
